This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Tuesday's Health Winners & Losers

AnorMed's (ANOR) shares jumped after Millennium Pharmaceuticals (MLNM) said it plans to acquire the company in a deal worth $515 million. Anormed has agreed to support the deal, which represents a 40% premium to an unsolicited tender offer from Genzyme (GENZ). Shares jumped 26% to $12.64.

AngioDynamics (ANGO - Get Report) said earnings rose during the first quarter, sending shares up 13.8% to $21.90. Sales for the quarter were $20.3 million, up 24% from a year ago.

CytRx (CYTR - Get Report) lost 26.8% to $1.34 after the company said its Lou Gehrig's disease drug arimoclomol did not show a significant change in disease progression. The trial did meet its primary goal of proving the drug's safety and tolerability, however.

Elan's (ELN) shares sank Tuesday after a Piper Jaffray analyst said sales of the company's multiple sclerosis drug Tysabri could be lower than she expected. Shares were trading 2.2% lower to $15.52.

PDI's (PDII) shares dropped 9.5% to $11.89 after the company said GlaxoSmithKline (GSK - Get Report) doesn't intend to renew its contract sales agreement with the company in 2007.

Also falling were KOS Pharmaceuticals (KOSP), whose shares sank 7.1% to $44.17, Immunomedics (IMMU), down 6.2% to $1.66, Targacept (TRGT), 4.4% lower to $5.50, and Nymox Pharmaceutical (NYMX), off 5.3% to $3.79.

Health stocks rising during the trading day included Acorda Therapeutics (ACOR - Get Report), soaring 32.5% to $11.26, Critical Therapeutics (CRTX), gaining 10.7% to $2.38, MGI Pharma (MOGN), up 6.9% to $17.05, Crucell (CRXL), whose shares gained 6.6% to $24.31, and EpiCept (EPCT), up 26.5% to $2.15.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ELN $0.00 0.00%
ACOR $27.34 -5.43%
ANGO $12.50 0.64%
CYTR $3.36 0.00%
GSK $43.38 -0.22%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs